Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Part of paid clinical trials in Miami, Florida.

Sponsor
Baptist Health South Florida
Study ID
NCT03490760
Phase
PHASE2
Status
Terminated

Conditions

  • Adenocarcinoma of the Pancreas

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks
  • Radiation Therapy — RADIATION
    24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.

Study Details

This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.

Key Dates

Start date
Nov 9, 2018
Status verified
Sep 2023
Primary completion
Jul 9, 2020
Completion
Jul 9, 2020

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab plus Radiation Therapy
    Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks plus 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.

Primary Outcome Measure

Progression Free Survival [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Miami Cancer Institute at Baptist Health, Inc.MiamiFlorida33176-

Find similar trials in Miami, FL

By research site
Miami Cancer Institute at Baptist Health, Inc.· Miami, FL

Related Studies